samsung
bioepis
biogen
announce
ema
filing
acceptance
proposed
biosimilar
referencing
ranibizumab
incheon
south
korea
cambridge
globe
newswire
samsung
bioepis
biogen
nasdaq
biib
today
announced
european
medicines
agency
ema
accepted
review
marketing
authorisation
application
proposed
biosimilar
referencing
ranibizumab
ranibizumab
vascular
endothelial
growth
factor
retinal
vascular
disorders
leading
cause
blindness
approved
join
growing
number
biosimilars
developed
samsung
bioepis
commercialized
biogen
ema
filing
acceptance
ranibizumab
demonstrates
productive
collaboration
samsung
bioepis
biogen
brings
us
closer
shared
goal
offering
new
affordable
treatment
options
people
retinal
vascular
disorders
said
hee
kyung
kim
senior
vice
president
clinical
sciences
regulatory
affairs
division
lead
samsung
bioepis
believe
potential
meaningful
new
offering
patients
retinal
vascular
disorders
look
forward
continued
engagement
ema
throughout
review
ema
acceptance
ranibizumab
application
important
step
work
bring
new
potential
treatment
option
patients
retinal
vascular
disorders
would
represent
significant
addition
biosimilar
portfolio
said
ian
henshaw
senior
vice
president
global
head
biosimilars
biogen
believe
biosimilar
offerings
essential
collaborate
payers
health
authorities
globally
goal
creating
budget
headroom
fund
innovation
ensure
sustainable
healthcare
samsung
bioepis
announced
november
entered
new
commercialization
agreement
biogen
two
ophthalmology
biosimilar
candidates
ranibizumab
aflibercept
united
states
canada
europe
japan
australia
samsung
bioepis
ltd
established
samsung
bioepis
biopharmaceutical
company
committed
realizing
healthcare
accessible
everyone
innovations
product
development
firm
commitment
quality
samsung
bioepis
aims
become
world
leading
biopharmaceutical
company
samsung
bioepis
continues
advance
broad
pipeline
biosimilar
candidates
cover
spectrum
therapeutic
areas
including
immunology
oncology
ophthalmology
hematology
samsung
bioepis
joint
venture
samsung
biologics
biogen
information
please
visit
follow
us
social
media
twitter
linkedin
biogen
biogen
mission
clear
pioneers
neuroscience
biogen
discovers
develops
delivers
worldwide
innovative
therapies
people
living
serious
neurological
neurodegenerative
diseases
well
related
therapeutic
adjacencies
one
world
first
global
biotechnology
companies
biogen
founded
charles
weissmann
heinz
schaller
kenneth
murray
nobel
prize
winners
walter
gilbert
phillip
sharp
today
leading
portfolio
medicines
treat
multiple
sclerosis
introduced
first
approved
treatment
spinal
muscular
atrophy
commercializes
biosimilars
advanced
biologics
focused
advancing
research
programs
multiple
sclerosis
neuroimmunology
alzheimer
disease
dementia
neuromuscular
disorders
movement
disorders
ophthalmology
immunology
neurocognitive
disorders
acute
neurology
pain
routinely
post
information
may
important
investors
website
learn
please
visit
http
follow
us
social
media
twitter
linkedin
facebook
youtube
safe
harbor
news
release
contains
statements
including
statements
made
pursuant
safe
harbor
provisions
private
securities
litigation
reform
act
relating
potential
benefits
safety
efficacy
timing
status
current
future
regulatory
filings
risks
uncertainties
associated
drug
development
commercialization
including
potential
biogen
commercial
business
pipeline
programs
including
anticipated
benefits
potential
biogen
collaboration
arrangements
samsung
bioepis
biogen
strategy
plans
potential
cost
healthcare
savings
related
biosimilars
statements
may
accompanied
words
aim
anticipate
believe
could
estimate
expect
forecast
intend
may
plan
potential
possible
would
words
terms
similar
meaning
drug
development
commercialization
involve
high
degree
risk
small
number
research
development
programs
result
commercialization
product
results
early
stage
clinical
trials
may
indicative
full
results
results
later
stage
larger
scale
clinical
trials
ensure
regulatory
approval
place
undue
reliance
statements
scientific
data
presented
statements
involve
risks
uncertainties
could
cause
actual
results
differ
materially
reflected
statements
including
without
limitation
actual
timing
content
submissions
decisions
made
regulatory
authorities
regarding
regulatory
submissions
may
take
longer
difficult
complete
expected
regulatory
authorities
may
require
additional
information
studies
may
fail
refuse
approve
may
delay
approval
risks
unexpected
costs
delays
unexpected
hurdles
uncertainty
success
development
potential
commercialization
may
impacted
among
things
level
preparedness
healthcare
providers
treat
patients
difficulties
obtaining
changes
availability
reimbursement
unexpected
difficulties
hurdles
occurrence
adverse
safety
events
unexpected
concerns
may
arise
additional
data
analysis
failure
protect
enforce
data
intellectual
property
proprietary
rights
uncertainties
relating
intellectual
property
claims
challenges
risks
legal
actions
regulatory
scrutiny
challenges
biosimilars
direct
indirect
impacts
ongoing
pandemic
biogen
business
results
operations
financial
condition
risks
business
internationally
including
currency
exchange
rate
fluctuations
product
liability
claims
third
party
collaboration
risks
foregoing
sets
forth
many
factors
could
cause
actual
results
differ
biogen
expectations
statement
investors
consider
cautionary
statement
well
risk
factors
identified
biogen
recent
annual
quarterly
report
reports
biogen
filed
securities
exchange
commission
statements
based
biogen
current
beliefs
expectations
speak
date
news
release
biogen
undertake
obligation
publicly
update
statements
whether
result
new
information
future
developments
otherwise
media
contact
samsung
bioepis
eu
news
release
yoon
kim
us
news
release
anna
nayun
kim
media
contact
biogen
investors
joe
mara
ir
media
david
caouette
